Omeros Corporation OMER
Analyst Ratings
- Consensus
- Buy — 3 Buy · 1 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $38.00 (+97.1% upside)
Key Stats
- Today's Range
- $18.41 – $19.58
- 50-Day Range
- $6.70 – $19.58
- 52-Week Range
- $3.34 – $19.58
- Volume
- 1.29 million shs
- Average Volume
- 2.09 million shs
- Market Cap
- $1.33 billion
- P/E Ratio
- 11.21
- Dividend Yield
- —
Valuation
- P/E Ratio
- 11.21
- Price / Book
- -25.92
- Price / Sales
- 34.65
Short Interest
- Short Interest
- 9.61%
- Days to Cover
- 19.62
Financials (TTM)
- Revenue
- $38.42 million
- Net Income
- $124.83 million
- Net Margin
- 324.88%
- Return on Equity
- -243.09%
- Debt-to-Equity
- —
About Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Related Stocks
Compare head-to-head: OMER vs LLY·OMER vs JNJ·OMER vs ABBV·OMER vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.